Medline (NASDAQ: MDLN) Investor Investigation
For Investors Who Bought Medline Stock Between December 17, 2025 and August 4, 2026 | Serving PA, NJ, NY, MD & DC
Short answer. The Siddons Law Firm is investigating whether Medline Inc. (NASDAQ: MDLN) gave investors accurate information about the quality of its manufacturing and its standing with the FDA. On June 2, 2026, an FDA warning letter about bacteria found in samples of finished product at Medline’s Waukegan, Illinois drug plant became public, and the stock fell 7.2 percent. On August 5, 2026, Medline cut its 2026 profit outlook, naming quality remediation among the reasons, and the stock fell 12.8 percent. If you lost $100,000 or more in Medline stock, or you are a current or former employee with firsthand knowledge, email msiddons@siddonslaw.com.
Last updated October 1, 2026.
Tell Us About Your Medline Loss
Email msiddons@siddonslaw.com or use the form below. Give us the dates you bought and sold MDLN, the number of shares and the approximate amount you lost. Tell us if you work or have worked for Medline. We will reply with the list of documents we need.
Key Facts
| Company | Medline Inc. (NASDAQ: MDLN), Northfield, Illinois |
|---|---|
| What happened | An FDA warning letter about the Waukegan, Illinois drug plant became public on June 2, 2026. On August 5, 2026, Medline cut its 2026 adjusted EBITDA outlook from $3.5 to $3.6 billion to $3.3 to $3.4 billion. |
| Stock price, June 2026 | Closed at $35.75 on June 1, 2026 and $33.19 on June 2, 2026, a fall of 7.2 percent |
| Stock price, August 2026 | Closed at $42.04 on August 4, 2026 and $36.67 on August 5, 2026, a fall of 12.8 percent |
| Stock offerings | Initial public offering on December 17, 2025 at $29.00 a share. Second offering priced March 4, 2026 at $41.00. Third offering priced May 21, 2026 at $37.00. |
| Period under review | Purchases from December 17, 2025 through August 4, 2026 |
| Has a case been filed? | No securities class action has been filed that we know of as of October 1, 2026. |
| Deadline to ask to lead the case | None yet. The 60-day period starts when the first case is filed and a notice is published. |
| Sources | FDA warning letter, May 28, 2026; Medline second quarter 2026 results. Full list below. |
What Happened at Medline?
Medline makes and distributes medical supplies. It sold stock to the public for the first time on December 17, 2025. In the months that followed, the FDA sent the company two warning letters about two of its plants, and the company later lowered its profit outlook. The dates are below.
| December 17, 2025 | Initial public offering. Medline sold 248,439,654 shares of Class A common stock at $29.00 a share. The stock began trading on NASDAQ. |
| March 4, 2026 | A second offering was priced: 75,000,000 shares at $41.00 a share. The sellers were existing stockholders. Medline received none of the money. |
| March 25, 2026 | The FDA sent a warning letter about Medline’s medical device plant in Glens Falls, New York, which it had inspected from December 1 to December 12, 2025. The letter cites problems with corrective action, cleaning and design verification. It refers to 221 complaints and 177 medical device reports about syringes disconnecting. |
| May 6, 2026 | Medline reported first quarter results and kept its adjusted EBITDA outlook at $3.5 to $3.6 billion. |
| May 21, 2026 | A third offering was priced: 72,554,594 shares at $37.00 a share. The sellers were again existing stockholders. The sale closed on May 28, 2026. |
| May 28, 2026 | The FDA sent a warning letter about Medline’s drug plant in Waukegan, Illinois, which it had inspected from October 6 to October 14, 2025. The letter says the bacterium Bacillus cereus was found in samples of finished product on about nine occasions between June 2, 2023 and August 27, 2025. It says the FDA had raised the problem on a Form 483 in January 2025 and at a regulatory meeting in May 2025. The FDA called Medline’s response inadequate and told the company to assess its manufacturing operations worldwide. |
| June 2, 2026 | The Waukegan letter became public. Medline stock closed at $33.19, down from $35.75 the day before, a fall of 7.2 percent. |
| August 5, 2026 | Medline reported second quarter results and cut its 2026 adjusted EBITDA outlook to $3.3 to $3.4 billion. It gave four reasons: inflation tied to the Middle East conflict, operational investments, quality remediation efforts and softness in its retail channel. The stock closed at $36.67, down from $42.04 the day before, a fall of 12.8 percent. |
What Had Medline Told Investors Before That?
Before the FDA letters became public, Medline made these statements to investors:
- In the registration statement for its initial public offering, as amended on December 8, 2025, Medline said it had a quality team of more than 2,400 employees and that every Medline-brand product meets its quality standards. It cited a complaint-free rate above 99.99 percent.
- On May 6, 2026, Medline kept its adjusted EBITDA outlook at $3.5 to $3.6 billion. The press release did not mention the FDA. Three months later the company lowered that outlook and named quality remediation as one of the reasons.
According to the FDA’s May 28, 2026 letter, the agency had raised the Waukegan problem with Medline in January 2025 and again in May 2025. Both dates are before the initial public offering.
What Is the Firm Investigating?
We are investigating whether Medline’s statements about the quality of its manufacturing and its standing with the FDA were accurate and complete when they were made, and whether investors who bought the stock between December 17, 2025 and August 4, 2026 paid more than it was worth as a result. Those questions arise under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.
Medline stock was sold to the public in three offerings in less than six months. We are also reviewing whether the offering papers left out or misstated important facts. Under Section 11 of the Securities Act of 1933, a buyer in an offering does not have to prove the company meant to mislead.
This is an investigation. No court has found that Medline, its officers or its stockholders did anything wrong.
Who Should Contact the Firm?
- Investors who lost $100,000 or more in Medline stock bought between December 17, 2025 and August 4, 2026. Shares held in an IRA or other retirement account count.
- Buyers in the March 2026 offering at $41.00 or the May 2026 offering at $37.00.
- Trusts, estates, retirement plans, partnerships and businesses that held Medline stock during that period.
- Current and former Medline employees, including people who worked at the Waukegan, Illinois and Glens Falls, New York plants, who know firsthand what the company knew about product quality and the FDA inspections. Do not send company documents. Tell us in your own words what you saw. You may also qualify for a whistleblower award.
If you lost less than $100,000, you generally do not need your own lawyer. Keep your trade confirmations and account statements. If a class action is filed and settles, you will need them to file a claim.
What Should I Send?
Send five facts to msiddons@siddonslaw.com:
- The dates you bought and sold MDLN.
- The number of shares.
- The prices you paid, if you have them.
- Your approximate loss.
- Whether you work or have worked for Medline.
Do not send documents through this website. We will reply with the list of documents we need.
What Are the Deadlines?
No securities class action against Medline has been filed that we know of as of October 1, 2026. When the first case is filed, a notice is published, and investors have 60 days from that notice to ask the court to appoint them lead plaintiff. We will post the date here when it is set.
A securities fraud claim generally must be filed within two years after the facts are discovered and no later than five years after the violation. A claim under Section 11 has shorter limits: generally one year after the facts are discovered and no later than three years after the offering.
Frequently Asked Questions
Has a lawsuit been filed against Medline?
Not that we know of as of October 1, 2026. The matter is under investigation. If a case is filed, we will post the court, the class period and the lead plaintiff deadline on this page.
I bought Medline in the IPO at $29.00. Do I have a claim?
Maybe not. A claim requires a loss. Medline closed at $34.66 on September 24, 2026, which is above the IPO price. Investors who bought later at higher prices, including in the March 2026 offering at $41.00 and the May 2026 offering at $37.00, are more likely to have a loss.
I lost less than $100,000 in MDLN. What should I do?
Keep your trade confirmations and account statements. If a class action is filed and you bought during the class period, you are generally a member of the class without doing anything. If the case settles, you will need your records to file a claim.
I still own my MDLN shares. Does that matter?
No. What matters is that you bought during the period under review and held shares when the news came out. Investors who sold after the price fell, and investors who still hold, can both have a claim.
I work for Medline. Can I contact the firm?
Yes. What you tell us is confidential. Do not send company documents or anything the company’s lawyers told you. Federal law protects employees who report securities violations from retaliation, and the SEC whistleblower program pays an award of 10 to 30 percent of the money collected when a report leads to sanctions of more than $1 million.
What does it cost to have my Medline loss reviewed?
The first conversation is free. If we take your matter, the fee terms are put in writing before any work begins.
Sources
- FDA warning letter to Medline Inc, May 28, 2026 (Waukegan, Illinois)
- FDA warning letter to Medline Industries, LP, March 25, 2026 (Glens Falls, New York)
- Medline Inc., Amendment No. 2 to Form S-1, filed with the SEC December 8, 2025
- Medline press release, closing of initial public offering, December 18, 2025
- Medline press release, pricing of secondary offering, March 4, 2026
- Medline press release, closing of secondary offering, May 28, 2026
- Medline press release, first quarter 2026 results, May 6, 2026
- Medline press release, second quarter 2026 results, August 5, 2026
Email Us About Medline
Email msiddons@siddonslaw.com with the dates you bought and sold MDLN, the number of shares and your approximate loss. Attorney Michael A. Siddons represents investors in Pennsylvania, New Jersey, New York, Maryland and Washington, D.C.